Rivaroxaban Apixaban Edoxaban Standard dose 150 mg twice daily 20 mg once daily 5 mg twice daily 60 mg once daily Dose reduction criteria
CrCl, creatinine clearance; RCT, randomized clinical trial; U.S., United States. *Dabigatran did not have specific dose reduction criteria for selected patients between the 150 mg and 110 mg twice daily doses. In the 2016 ESC guideline, they recommended as follow: "When dabigatran is used, a reduced dose (110 mg twice daily) may be considered in patients >75 years to reduce the risk of bleeding (class IIb recommendation, level of evidence B)." Reflecting these backgrounds, in the present study, dabigatran dose reduction on label as a recommendation rather than strict dose reduction criteria. Both doses (150 mg and 110 mg twice daily) can be prescribed without any restrictions, † 150 mg or 110 mg twice daily should be selected based on an individual assessment in patients aged between 75-80 years old, moderate renal impairment, gastritis, esophagitis, gastroesophageal reflux disease, or patients with an increased risk of bleeding.
